| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 20th January 2021 | Oliver Christian Bennett | 4,399 | Open or private sale | $4.49 | $19,752.39 |
| 13th January 2021 | Hove Caroline F. Van | 1,973 | Open or private sale | $4.71 | $9,300.52 |
| 12th January 2021 | Keith J Sullivan | 125,000 | Grant/award etc. | $0.00 | |
| 7th January 2021 | Oliver Christian Bennett | 3,665 | Payment by withholding | $4.26 | $15,612.90 |
| 11th November 2020 | Kevin C Oboyle | 16,306 | Disposition due to a tender of shares in a change of control transaction | $30.75 | $501,409.50 |
| 8th November 2020 | Hove Caroline F. Van | 100,000 | Grant/award etc. | $0.00 | |
| 12th October 2020 | Paul Sean Little | 50,000 | Grant/award etc. | $0.00 | |
| 12th October 2020 | Oliver Christian Bennett | 50,000 | Grant/award etc. | $0.00 | |
| 3rd September 2020 | Paul Sean Little | 5,763 | Payment by withholding | $3.54 | $20,401.02 |
| 14th July 2020 | Keith J Sullivan | 500,000 | Grant/award etc. | $0.00 |
Sientra
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Sientra, Inc. engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra,. AlloX2, Dermaspan, Softspan and BIOCORNEUM.
Ticker: SIEN
Sector: Healthcare
Industry: Medical Devices
SEC Central Index Key (CIK): 1551693
Employees: 259
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $496 Th for the period Apr 2020 to Jun 2020 in the context of all up
Restructuring Charges of $2 M for the period Jan 2020 to Jun 2020 in the context of all up
Restructuring Charges of $2 M for the period Jan 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $122 Th for the period Jan 2020 to Jun 2020 in the context of Other restructuring
Restructuring Charges of $174 Th for the period Jan 2020 to Jun 2020 in the context of Duplicate operating costs
Restructuring Charges of $831 Th for the period Jan 2020 to Jun 2020 in the context of Breast product
Restructuring Charges of $1 M for the period Jan 2020 to Jun 2020 in the context of Miradry
Restructuring Charges of $1 M for the period Nov 2019 to Jun 2020 in the context of Breast product
Restructuring Charges of $2 M for the period Nov 2019 to Jun 2020 in the context of Miradry
Restructuring Charges of $3 M for the period Nov 2019 to Jun 2020 in the context of all up
Restructuring Charges of $499 Th for the period Jan 2019 to Dec 2019 in the context of Breast product
Restructuring Charges of $584 Th for the period Jan 2019 to Dec 2019 in the context of Miradry
Restructuring Charges of $1 M for the period Jan 2019 to Dec 2019 in the context of all up
Fundamentals
Cash at Carrying Value: $72 M (0%)
Inventory, Net: $46 M (0%)
Assets, Current: $145 M (-8%)
Property, Plant and Equipment, Net: $13 M (0%)
Other Assets, Noncurrent: $9 M (6%)
Assets: $185 M (0%)
Accounts Payable, Current: $4 M (-59%)
Accrued Liabilities, Current: $23 M (0%)
Liabilities, Current: $51 M (-28%)
Long-term Debt, Excluding Current Maturities: $63 M (65%)
Liabilities: $163 M (33%)
Common Stock, Value, Issued: $503 Th (1%)
Common Stock, Shares, Issued: $50 M (1%)
Additional Paid in Capital, Common Stock: $554 M (0%)
Retained Earnings (Accumulated Deficit): $532 M (13%)
Stockholders' Equity (Parent): $22 M (0%)
Liabilities and Equity: $185 M (-9%)
Revenue: $12 M (0%)
Cost of Revenue: $6 M (-55%)
Gross Margin: $7 M (-59%)
Research and Development: $3 M (-51%)
Sales and Marketing: $8 M (-67%)
General and Administrative Expenses: $8 M (-53%)
Restructuring Charges: $496 Th (-77%)
Operating Income/Loss: $12 M (0%)
Other Income, net: $22 M (-6%)
News
Sientra Reports Third Quarter 2020 Financial Results
9th November 2020
Sientra to Participate in Upcoming Virtual Investor Conferences
6th November 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020